Oren Zwang1, Richard K Albert. 1. Denver Health Medical Center and University of Colorado Health Sciences Center, Denver, Colorado 80204-4507, USA.
Abstract
BACKGROUND: Approximately 90% of all blood cultures grow no organisms (ie, are true negatives), and 5% are thought to represent contaminants (ie, are false positives). The cost effectiveness of blood cultures could therefore be improved by developing rules that safely decreased the number of cultures drawn from patients with a low likelihood of having bacteremia and/or by improving the process of obtaining cultures, thereby decreasing the number of contaminants. We analyzed the potential effects of these two approaches. METHODS: We annualized the hospital costs and lengths of stay for patients with true-negative and false-positive blood cultures from a retrospective analysis of 939 sets of cultures drawn in January 2002. RESULTS: Of the 939 blood culture sets, 816 (87%) were true negatives and generated annualized costs of approximately 750,000 dollars. Although only 56 (6%) of the blood culture sets were false positives, they resulted in annualized costs of 1.4-1.8 million dollars and added an estimated 1450-2200 extra hospital days/year. CONCLUSIONS: Despite there being nearly 15 times as many true-negative blood cultures as false positive ones, far greater improvements in resource utilization would result from reducing the number of contaminated blood cultures than by reducing the number of true negatives. The potential savings from this approach are of sufficient magnitude to justify investing considerable resources to attaining this goal. (c) 2006 Society of Hospital Medicine.
BACKGROUND: Approximately 90% of all blood cultures grow no organisms (ie, are true negatives), and 5% are thought to represent contaminants (ie, are false positives). The cost effectiveness of blood cultures could therefore be improved by developing rules that safely decreased the number of cultures drawn from patients with a low likelihood of having bacteremia and/or by improving the process of obtaining cultures, thereby decreasing the number of contaminants. We analyzed the potential effects of these two approaches. METHODS: We annualized the hospital costs and lengths of stay for patients with true-negative and false-positive blood cultures from a retrospective analysis of 939 sets of cultures drawn in January 2002. RESULTS: Of the 939 blood culture sets, 816 (87%) were true negatives and generated annualized costs of approximately 750,000 dollars. Although only 56 (6%) of the blood culture sets were false positives, they resulted in annualized costs of 1.4-1.8 million dollars and added an estimated 1450-2200 extra hospital days/year. CONCLUSIONS: Despite there being nearly 15 times as many true-negative blood cultures as false positive ones, far greater improvements in resource utilization would result from reducing the number of contaminated blood cultures than by reducing the number of true negatives. The potential savings from this approach are of sufficient magnitude to justify investing considerable resources to attaining this goal. (c) 2006 Society of Hospital Medicine.
Authors: A Page; S O'Rourke; M Brennan; L Clooney; D Le Blanc; J Griffin; M Eogan; R J Drew Journal: Ir J Med Sci Date: 2017-02-14 Impact factor: 1.568
Authors: Wesley H Self; Thomas R Talbot; Barbara R Paul; Sean P Collins; Michael J Ward Journal: Infect Control Hosp Epidemiol Date: 2014-06-20 Impact factor: 3.254
Authors: Gary V Doern; Karen C Carroll; Daniel J Diekema; Kevin W Garey; Mark E Rupp; Melvin P Weinstein; Daniel J Sexton Journal: Clin Microbiol Rev Date: 2019-10-30 Impact factor: 26.132
Authors: Susan R Snyder; Alessandra M Favoretto; Rich Ann Baetz; James H Derzon; Bereneice M Madison; Diana Mass; Colleen S Shaw; Christopher D Layfield; Robert H Christenson; Edward B Liebow Journal: Clin Biochem Date: 2012-06-16 Impact factor: 3.281
Authors: Prashant Mahajan; Nathan Kuppermann; Asuncion Mejias; Nicolas Suarez; Damien Chaussabel; T Charles Casper; Bennett Smith; Elizabeth R Alpern; Jennifer Anders; Shireen M Atabaki; Jonathan E Bennett; Stephen Blumberg; Bema Bonsu; Dominic Borgialli; Anne Brayer; Lorin Browne; Daniel M Cohen; Ellen F Crain; Andrea T Cruz; Peter S Dayan; Rajender Gattu; Richard Greenberg; John D Hoyle; David M Jaffe; Deborah A Levine; Kathleen Lillis; James G Linakis; Jared Muenzer; Lise E Nigrovic; Elizabeth C Powell; Alexander J Rogers; Genie Roosevelt; Richard M Ruddy; Mary Saunders; Michael G Tunik; Leah Tzimenatos; Melissa Vitale; J Michael Dean; Octavio Ramilo Journal: JAMA Date: 2016 Aug 23-30 Impact factor: 56.272
Authors: Valeria Fabre; Eili Klein; Alejandra B Salinas; George Jones; Karen C Carroll; Aaron M Milstone; Joe Amoah; Yea-Jen Hsu; Avinash Gadala; Sanjay Desai; Amit Goyal; David Furfaro; Jacquelyn Zimmerman; Susan Lin; Sara E Cosgrove Journal: J Clin Microbiol Date: 2020-09-22 Impact factor: 5.948